Skip to content
Review Open access

Restoring Cancer Genomes: Functional Mutation Correction as a Platform for Precision Oncology

Jul 2026 · Human Gene Therapy · Vol 37, pp. 663 - 669 · 0 citations · 60 references
Medicine

TL;DR

It is proposed that systematic reversal of cancer mutations represents a conceptual shift from observing mutational landscapes to actively testing their biological necessity and provides a scalable functional platform to stratify drivers, interrogate variants of uncertain significance, and refine precision diagnostics.

Abstract

Cancer genome sequencing has uncovered an extensive landscape of somatic mutations. However, determining which of these alterations are biologically consequential and therapeutically actionable remains a central challenge in oncology. CRISPR-based genome editing now enables precise correction of oncogenic mutations within their endogenous genomic context. Recent work demonstrates that repairing cancer hotspot mutations restores conserved tumor-relevant transcriptional programs across diverse tumor types, revealing tumor-agnostic dependencies. Beyond therapeutic implications, this mutation-correction framework provides a scalable functional platform to stratify drivers, interrogate variants of uncertain significance, and refine precision diagnostics. This perspective discusses how programmable mutation correction advances (i) mechanistic cancer biology, (ii) personalized cancer diagnostics, and (iii) next-generation precision gene therapies. We propose that systematic reversal of cancer mutations represents a conceptual shift from observing mutational landscapes to actively testing their biological necessity.

Read PDF

Similar papers

Review Open access Aug 2026

A Review on Screen, Shield, Stop: Halting Hereditary Cancer through Genomic Surveillance and Crispr – Cas9

Hereditary cancers account for approximately 5–10% of all cancer cases and arise due to inherited pathogenic variants in cancer susceptibility genes. Advances in genomic medicine have transformed the early identification of individuals at high risk, enabling timely surveillance, preventive interventions, and personaliz...

K. C., Marian Joseph, L. K · 0 citations
Review Open access Aug 2026

CRISPR Functional Genomics in Precision Oncology: Integrating Single-Cell Multi-Omics for Cancer Vulnerability Discovery

A new conceptual model is introduced, called the Integrated Functional Precision Oncology (IFPO) Framework, that brings together functional genomic perturbation, single-cell multi-omics, computational systems biology, and clinical translation and offers directions for further progress of precision cancer treatment base...

O. Oluwadare, M. Frankpeace, Oluwabukunmi M. Oluwaniran et al. · 1 citation
#gene editing Review Sep 2026

CRISPR and Gene Editing Approaches in Prostate Cancer: Clinical Applications and Therapeutic Potential.

Overall, CRISPR-based technologies show considerable potential to support precision oncology in prostate cancer by enabling molecularly informed therapeutic strategies and addressing treatment resistance, although challenges related to delivery, off-target effects, tumor heterogeneity, immunogenicity, and clinical tran...

Vaibhavkumar Patel, Pratichi Singh, S. Dutta et al. · 0 citations
Open access Sep 2026

Genomic foundation model-derived disruption profiling links somatic mutations to cancer biology and clinical outcomes

Cancer genomics has concentrated on individual mutations, overlooking whether somatic mutations can accumulate to produce partial, gene-level disruption with biological and clinical consequences. Sequence-to-function models can quantify these effects directly from DNA sequence. Here, we use AlphaGenome and AlphaMissens...

A. Nayak, Travita Lee, V. Agarwal et al. · 0 citations
Review Open access Oct 2026

KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine

KRAS is one of the most frequently altered oncogenic drivers across human solid tumors and has long represented a central challenge in precision oncology. The clinical success of covalent KRAS G12C inhibitors has transformed a historically “undruggable” target into a tractable therapeutic class, but durable benefit rem...

Jia-Ying Cai, Yi-Min Wu, Xing Jia et al. · 0 citations
Review Open access Sep 2026

Hereditary breast cancer: emerging roles of non-coding RNAs

The need for integrative approaches that combine genomic insights, advanced technologies, and personalized medicine to improve breast cancer prevention and treatment is emphasized, emphasizing the need for integrative approaches that combine genomic insights, advanced technologies, and personalized medicine to improve...

Zhen-Shan Yang, Dipanjan Guha, Ling Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.